🔍

ERIS - ERIS Lifescience

📊 NSE: ERIS 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/13/2025 21:56

📢 Recent Corporate Announcements

Eris Lifesciences Reports Non-Compliance Observations at Swiss Parenterals Units 1 and 2

🔵 WATCH ⭐ 7/10

REGULATORY 📅 20 Apr 2026, 10:25 PM

Eris Lifesciences' subsidiary, Swiss Parenterals, has received non-compliance observations from HALMED (Croatia) following an inspection of its Ahmedabad facilities from March 9th to 13th, 2026. The observations affect Unit 1 (general injectables) and Unit 2 (betalactam injectables) and are procedural in nature, requiring improvements to meet EU GMP standards. While the company expects minimal impact on current business, the commercialization of its EU-CDMO product pipeline will face delays. Eris is currently preparing remediation actions and Corrective and Preventive Actions (CAPA) to seek a follow-on inspection.

Inspection conducted by HALMED (Croatia) at Swiss Parenterals Units 1 and 2 from March 9 to 13, 2026
Observations pertain to procedural improvements for compliance with EU GMP Directive 2017/1572
Direct impact includes a delay in the commercialization of the EU-CDMO product pipeline
Company states there is minimal impact on existing business operations
Next steps involve executing remediation actions and requesting a follow-on inspection from the agency

💡 Investors should monitor the timeline for CAPA submission and the subsequent follow-up inspection results, as any prolonged delay in the EU-CDMO pipeline could impact long-term growth estimates.

Eris Lifesciences Submits SEBI Compliance Certificate for Q4 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 10 Apr 2026, 05:46 PM

Eris Lifesciences has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations for the quarter ended March 31, 2026. The certificate, issued by the Registrar and Share Transfer Agent (RTA) MUFG Intime India Private Limited, confirms that all securities received for dematerialization were processed within prescribed timelines. It further verifies that physical certificates were mutilated and cancelled, and the names of depositories were updated in the register of members. This is a standard procedural disclosure required by all listed entities in India.

Compliance certificate submitted for the quarter ended March 31, 2026.
Confirmation provided by RTA MUFG Intime India Private Limited (formerly Link Intime).
Verification that dematerialized securities are listed on BSE and NSE.
Physical security certificates were mutilated and cancelled as per SEBI guidelines.
The filing confirms adherence to the prescribed timelines for depository updates.

💡 No action is required from investors as this is a routine regulatory filing confirming administrative compliance.

Eris Lifesciences to Close Trading Window from April 1, 2026, for Q4 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Mar 2026, 05:59 PM

Eris Lifesciences Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting April 01, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the upcoming financial results. The closure pertains to the audited financial results for the quarter and full financial year ending March 31, 2026. The window will remain closed until 48 hours after the results are officially declared to the public.

Trading window closure begins on April 01, 2026, for all designated persons.
Closure is related to the Audited Financial Results for the quarter and year ending March 31, 2026.
The window will reopen 48 hours after the financial results are made public.
Compliance is mandated under SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 This is a routine regulatory announcement with no direct impact on stock valuation. Investors should look forward to the actual Q4 and FY26 earnings release for fundamental performance updates.

Eris Lifesciences Partners with Natco Pharma to Launch Generic Semaglutide in March 2026

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 20 Mar 2026, 04:08 PM

Eris Lifesciences has entered a strategic partnership with Natco Pharma to commercialize generic Semaglutide in India, a transformative therapy for Type 2 diabetes and weight management. Natco has secured CDSCO approval for manufacturing, with the commercial launch slated for March 2026. This move strengthens Eris's position in the metabolic care segment, leveraging its existing network of 5,00,000+ retail pharmacies and 5,000 stockists. The company has invested approximately INR 4,000 crore over the last three years to diversify its portfolio and scale its chronic therapy presence.

Strategic partnership with Natco Pharma for the launch of generic Semaglutide under the brand 'Sundae'.
Commercial launch expected in March 2026 following CDSCO manufacturing approval for Natco.
Eris reported FY25 revenue of INR 2,894 crore and has grown operating profit 2.6x over the last 5 years.
The company maintains a strong diabetes franchise with a reach across 5,00,000+ retail pharmacies in India.
Total investment of ~INR 4,000 crore in the last 3 years towards technology and therapeutic diversification.

💡 Investors should monitor the launch execution in March 2026 as Semaglutide represents a high-growth opportunity in the Indian metabolic market. The stock remains a strong play on the chronic therapy segment given its aggressive portfolio expansion and 2.6x profit growth over five years.

Eris Lifesciences to Acquire Velbiom Probiotics Business for Rs 50 Crore

🟢 POSITIVE ⭐ 8/10

M&A 📅 20 Mar 2026, 03:29 PM

Eris Lifesciences has entered into a Business Transfer Agreement to acquire the branded probiotic portfolio of Velbiom Probiotics Private Limited for Rs 50 crore. The acquisition, executed on a slump sale basis, includes specialized formulations for metabolic health, gut wellness, and women’s health. Velbiom reported revenues of Rs 16.02 crore for the first nine months of FY26, showing steady performance compared to Rs 19.64 crore in FY25. This strategic move allows Eris to deepen its presence in the high-growth microbiome-based therapy and research segment.

Acquisition of Velbiom Probiotics' branded business for a total cash consideration of Rs 50 crore
Target business revenue stood at Rs 16.02 crore for 9M FY26 and Rs 19.64 crore for FY25
Portfolio focuses on high-growth areas including metabolic health, gut wellness, and women’s health
Transaction structured as a slump sale on a going concern basis with no related party involvement
Acquisition aims to leverage Velbiom's science-driven India-specific microbiome therapy research

💡 This is a positive bolt-on acquisition that strengthens Eris's specialty portfolio; investors should monitor the integration and its contribution to margin expansion in future quarters.

Eris Lifesciences Appoints Vineet Varma as Independent Director for 5-Year Term

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 14 Mar 2026, 12:50 PM

Eris Lifesciences has announced the appointment of Mr. Vineet Varma as an Additional Director (Non-Executive, Independent) effective March 14, 2026. Mr. Varma is a veteran banker with over 25 years of experience in wholesale banking, transaction banking, and treasury management across international institutions like ABN Amro and FAB. The appointment is for a five-year term and is intended to strengthen the board's expertise in financial markets and corporate governance. This move follows the recommendation of the Nomination and Remuneration Committee and is subject to shareholder approval.

Appointment of Mr. Vineet Varma as Non-Executive Independent Director for a 5-year term starting March 14, 2026.
Mr. Varma brings over 25 years of management experience in wholesale banking and global markets.
He has previously held leadership roles at FAB, NBAD, and ABN Amro Banks.
Educational background includes London Business School and Shriram College of Commerce.
The board confirmed that the appointee is not debarred from holding office by SEBI or any other authority.

💡 This is a routine board-level appointment of a highly qualified professional; no immediate action is required. Investors should view the addition of banking expertise to the board as a positive step for financial oversight.

Eris Lifesciences to Hold One-on-One Meeting with Capital Group on March 19, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Mar 2026, 05:25 PM

Eris Lifesciences Limited has scheduled an in-person meeting with Capital Group on March 19, 2026, in Mumbai. The meeting is a one-on-one session featuring Mr. Krishnakumar Vaidyanathan as the management representative. This interaction is part of the company's routine investor relations activities under SEBI regulations. The company has clarified that only publicly available information will be discussed, with no unpublished price-sensitive information being shared.

One-on-one meeting scheduled with Capital Group for March 19, 2026, at 9:30 AM
In-person interaction to be held in Mumbai with management representative Krishnakumar Vaidyanathan
Compliance with SEBI Regulation 30 regarding the disclosure of institutional investor meetings
Discussion will be limited to publicly available documents and information

💡 Investors should view this as a routine engagement with a major institutional fund; no immediate action is required as no new material information will be disclosed.

Eris Lifesciences Allots 19,624 Equity Shares Under ESOP-2021 Scheme

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 12 Mar 2026, 12:12 PM

Eris Lifesciences has allotted 19,624 equity shares to employees following the exercise of options under its ESOP-2021 scheme. The allotment includes shares granted between 2022 and 2024 at exercise prices ranging from Rs. 510.32 to Rs. 728.16. As a result, the company's total paid-up share capital has increased to 13,85,42,887 equity shares. This is a routine administrative update with negligible impact on the overall equity structure.

Allotment of 19,624 equity shares of Re. 1 face value under the ESOP-2021 Scheme.
Exercise prices for the allotted shares were set at Rs. 510.32, Rs. 557.24, and Rs. 728.16.
Total paid-up share capital increased from Rs. 13,85,23,263 to Rs. 13,85,42,887.
The allotment represents a marginal dilution of approximately 0.014% of the total share capital.

💡 No action is required as this is a routine corporate event with minimal impact on shareholder value or EPS. Investors should focus on the company's quarterly financial performance and growth outlook.

Eris Lifesciences to Attend Investec India Promoter & Founder Conference on March 10, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Mar 2026, 10:33 AM

Eris Lifesciences Limited has scheduled its participation in the Investec India Promoter & Founder Conference 2026 on March 10, 2026. The company's management, including Promoter and Founder Mr. Amit Bakshi, will engage with institutional investors in Mumbai. The meetings will be conducted in physical format, featuring both one-on-one and group discussions. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during these interactions.

Participation in Investec India Promoter & Founder Conference 2026 on March 10, 2026
Management representation includes Founder Mr. Amit Bakshi and Ms. Kruti Raval
Meeting format includes physical 1x1 and group sessions in Mumbai
Discussions will be limited to publicly available information and documents

💡 No immediate action is required as this is a routine investor relations event. Investors may look for any updated investor presentations on the company's website following the conference.

Eris Lifesciences to Meet Ajanta India Fund on February 26, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Feb 2026, 02:55 PM

Eris Lifesciences Limited has announced an upcoming in-person meeting with Ajanta India Fund scheduled for February 26, 2026, in Mumbai. The meeting will feature Mr. Krishnakumar Vaidyanathan representing the company's management. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be discussed, and the interaction will be based on publicly available data. This is a routine engagement aimed at institutional investor relations.

Meeting scheduled with Ajanta India Fund for February 26, 2026, at 10:00 AM
The interaction will be an in-person meeting held in Mumbai
Management representation by Mr. Krishnakumar Vaidyanathan
Company confirms discussions will be limited to publicly available documents

💡 No immediate action is required as this is a routine investor meeting. Investors may look for any subsequent investor presentations or transcripts if the company chooses to publish them.

Eris Lifesciences Releases Q3 FY26 Analyst and Investor Call Transcript

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Feb 2026, 11:41 AM

Eris Lifesciences has informed the exchanges that the transcript for its Q3 and nine-month FY26 earnings conference call is now available. The call was held following the announcement of financial results for the period ended December 31, 2025. This document provides a detailed record of management's responses to analyst queries regarding business performance and future outlook. Investors can access the full text on the company's official website to gain deeper insights into the company's strategic direction.

Official transcript for the Q3 FY26 analyst and investor call has been published.
The call covered financial performance for the quarter and nine months ended December 31, 2025.
Document is available on the company's website under the financial results section.
Provides transparency on management commentary and strategic guidance given during the earnings call.

💡 Investors should review the transcript to understand management's stance on therapeutic segment growth and margin outlook. This is a routine but essential document for fundamental analysis.

Eris Lifesciences to Participate in IIFL Global Investors' Conference on February 25, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 19 Feb 2026, 04:09 PM

Eris Lifesciences Limited has announced its participation in the IIFL 17th Enterprising India Global Investors' Conference. The event is scheduled for February 25, 2026, in Mumbai and will feature physical 1x1 and group meetings. Management representatives Mr. Krishnakumar Vaidyanathan and Ms. Kruti Raval will represent the company. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be discussed during these interactions.

Participation in IIFL's 17th Enterprising India Global Investors' Conference on February 25, 2026
Management representatives include Mr. Krishnakumar Vaidyanathan and Ms. Kruti Raval
Meeting format includes physical 1x1 and group interactions in Mumbai
Discussions will be based on publicly available documents with no UPSI disclosure intended

💡 This is a routine investor relations update; investors should monitor for any investor presentations released following the conference for updated business outlooks.

Eris Lifesciences Releases Q3 FY26 Earnings Conference Call Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 13 Feb 2026, 10:29 PM

Eris Lifesciences has made the audio recording of its Q3 FY26 earnings conference call available to the public. The call, held on February 13, 2026, discussed the company's unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. This disclosure is a standard regulatory requirement under SEBI Listing Obligations. Investors can access the recording on the company's official website to understand management's commentary on recent performance and future growth strategies.

Recording of the Q3 FY26 earnings call held on February 13, 2026, is now available.
Covers financial results for the quarter and nine months ended December 31, 2025.
The recording is accessible via the company's investor relations website under the financials section.
Filing is in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 Investors should listen to the recording to gain insights into management's outlook on margins and therapeutic segment growth. No immediate action is required as this is a routine procedural update.

Eris Lifesciences Q3 FY26: Adj. PAT Surges 38.5%, International Business Grows 45%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 03:20 PM

Eris Lifesciences reported a robust Q3 FY26 with consolidated revenue growing 11% YoY to Rs. 807 crore and adjusted PAT rising 38.5% to Rs. 120 crore. The International Business was a standout performer, growing 45% YoY, while the Domestic Branded Formulations (DBF) segment maintained steady 10% growth. The company is strategically pruning its portfolio by discontinuing low-margin tail-end brands to focus on high-growth therapies like Insulins and GLP-1. Debt reduction remains on track with a target Net Debt/EBITDA ratio of under 1.5x by December 2026.

Consolidated Q3 Revenue grew 11% YoY to Rs. 807 crore with EBITDA margins improving to 34.9%.
International Business revenue surged 45% YoY to Rs. 111 crore, with FY27 revenue guidance of Rs. 550-600 crore.
RHI Cartridges market share tripled to 25% since the Biocon acquisition, meeting the company's stated strategic objective.
Decision to discontinue non-core tail-end brands will impact FY27 DBF revenue by 2% but improve core margins to ~39%.
Net Debt to TTM EBITDA reduced to 2.1x as of Dec 2025, with a clear path to <1.5x by Dec 2026.

💡 Investors should focus on the company's successful integration of acquisitions and its pivot towards high-margin chronic therapies like Insulins and the upcoming GLP-1 launch. The portfolio rationalization and debt reduction trajectory are positive indicators for long-term value creation.

Eris Lifesciences Q3 FY26 Net Profit Grows 25% YoY to ₹108.8 Cr; Revenue Up 11%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 01:24 PM

Eris Lifesciences reported a solid performance for Q3 FY26, with consolidated revenue growing 11% YoY to ₹807.45 crore. Net profit for the quarter increased by 25% YoY to ₹108.83 crore, despite an exceptional charge of ₹17.24 crore. On a sequential basis, while revenue grew slightly, net profit saw a decline from ₹134.47 crore in the previous quarter due to higher tax expenses and the exceptional item. The company's debt-to-equity ratio improved to 0.67 from 0.79 YoY, reflecting better leverage management.

Consolidated Revenue from operations grew 11% YoY to ₹807.45 crore in Q3 FY26.
Net Profit increased 25% YoY to ₹108.83 crore, even after accounting for a ₹17.24 crore exceptional item.
Nine-month (9M FY26) Net Profit stands at ₹368.40 crore, up significantly from ₹273.02 crore in 9M FY25.
Debt-Equity ratio improved to 0.67 from 0.79 in the year-ago period, indicating debt reduction.
Interest Service Coverage Ratio strengthened to 4.33 from 3.04 YoY, showing improved debt servicing capacity.

💡 Investors should view the strong YoY profit growth and improving debt profile as positive indicators of operational efficiency. The sequential dip in profit warrants monitoring of margins and tax impacts in upcoming quarters.

View All ERIS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Domestic Branded Formulations (DBF) grew 10% YoY in Q2 FY26 to INR 708 Cr and 11% in H1 FY26 to INR 1,410 Cr. The International Business revenue was INR 83 Cr in Q2 FY26, a slight decline of 1% YoY, and INR 152 Cr in H1 FY26, down 4% YoY due to capacity being utilized for validation batches.

Geographic Revenue Split

India (Domestic) remains the dominant market contributing approximately 89.4% of Q2 FY26 revenue. International markets, including Africa, Asia-Pacific, Latam, and CIS/Middle East, contribute the remaining 10.6%. The company targets increasing the Regulated Markets (EU/Brazil) share to 30% of revenue by FY27.

Profitability Margins

Gross Margin stood at 74.5% in Q2 FY26 compared to 74.9% in Q2 FY25. Net Profit Margin significantly improved to 17.0% in Q2 FY26 from 13.1% in the previous year, driven by a 17% reduction in interest costs and a 51% drop in depreciation expenses.

EBITDA Margin

Consolidated EBITDA margin improved by 65 bps YoY to 36.4% in Q2 FY26 (INR 288 Cr). The DBF segment maintained a high margin of 37.6%, while the acquired Biocon business saw a turnaround with margins expanding from 19% at acquisition to 32% in Q2 FY26.

Capital Expenditure

The company has front-loaded its capex, planning to invest INR 380 to INR 400 Cr over the next three quarters. This is part of a larger INR 750 to INR 800 Cr three-year capex plan (FY26-FY28) focused on Bhopal Phase 2, Swiss Unit-3, and Levim manufacturing.

Credit Rating & Borrowing

Net debt stood at INR 2,278 Cr as of September 2025. Finance costs decreased by 16.7% YoY to INR 50 Cr in Q2 FY26. The Net Debt-to-EBITDA ratio has been reduced from 4x to 2x over the last 18 months, with a target of 1.3x by December 2026.

⚙️ Operational Drivers

Raw Materials

Specific raw material names are not explicitly listed, but the company focuses on active pharmaceutical ingredients (APIs) for chronic therapies and specialized components for Insulin and GLP-1 injectables. Manufacturing costs are being optimized by shifting the Biocon portfolio to in-house production.

Capacity Expansion

Current manufacturing spans 6 locations. Planned expansions include Bhopal Phase 2 (INR 150 Cr), Swiss Unit-3 (INR 130 Cr), and a second round of investment in Levim Lifetech (INR 100 Cr) for Diabesity pipeline and DS manufacturing.

Raw Material Costs

Gross Profit was INR 590 Cr in Q2 FY26 (74.5% of revenue). The company is pursuing a strategy of in-house manufacturing for acquired brands to reduce third-party procurement costs and expand margins by FY27.

Manufacturing Efficiency

The Biocon business turnaround is a key efficiency metric, with margins rising to 32%. In-house manufacturing for these products is expected to provide further margin expansion starting in FY27.

Logistics & Distribution

Other expenses, which include distribution and marketing, were INR 164 Cr in Q2 FY26, representing 20.7% of revenue, down from 22.2% YoY, indicating improved distribution efficiency.

📈 Strategic Growth

Expected Growth Rate

11-15%

Growth Strategy

Growth will be driven by a '50% over market' target in domestic formulations, the launch of RHI cartridges in Dec-2025, and a massive scale-up in the EU-CDMO business which has an order book of INR 700-800 Cr. The company is also expanding into high-growth therapies like GLP-1 and Oncology.

Products & Services

Branded pharmaceutical formulations in oral anti-diabetes, cardiology, dermatology, nephrology, oncology, and women's health. Specific products include Insulins, GLP-1 injectables, and RHI cartridges.

Brand Portfolio

Eris, Oaknet, Swiss Parenterals, Biocon (acquired domestic business), and Eris BioNxt.

New Products/Services

Launch of RHI cartridges starting Dec-2025 and a robust Diabesity pipeline. The EU-CDMO business is expected to be a major contributor, with revenue visibility of INR 125-150 Cr in the near term.

Market Expansion

Expanding from India into Africa, Asia-Pacific, Latam, and the CIS/Middle East, with a current strategic focus on entering the European Union through a Specialty CDMO model.

Market Share & Ranking

Eris grew at 10% in Q2 FY26, which is 30% higher than the Indian Pharmaceutical Market (IPM) growth of 7.7%. In H1, it grew 11%, which is 42% over the IPM growth of 7.4%.

Strategic Alliances

30% equity stake in Levim Lifetech (Bio) with an agreement to enhance it to 49%. Joint Venture with Levim Lifetech Private Limited.

🌍 External Factors

Industry Trends

The industry is shifting toward biologics and complex injectables. Eris is positioning itself by investing in Insulin and GLP-1 capacities, expecting regulated markets to contribute 30% of revenue by FY27, up from <2% in FY24.

Competitive Landscape

Competes with major Indian pharmaceutical players in the domestic branded market and global CDMOs in the international segment.

Competitive Moat

Eris maintains a moat through its leadership in chronic therapies (Diabetes/Cardio) and high-entry-barrier manufacturing (Injectables/Biologics). Its shift toward a Specialty CDMO model for the EU provides long-term revenue stickiness.

Macro Economic Sensitivity

The business is sensitive to the growth of the Indian Pharmaceutical Market (IPM), consistently aiming to outperform it by 50%.

Consumer Behavior

Increasing demand for advanced diabetes management (Insulins/GLP-1) is driving the company's shift toward injectable formulations.

Geopolitical Risks

Expansion into Regulated Markets (EU) and Latam (Brazil) subjects the company to stringent international regulatory inspections and trade standards.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to ANVISA (Brazil) and EU-GMP standards. The company recently received ANVISA approval for its oral liquids line and is targeting inspections for oral solids and injectables in Jan-2026.

Taxation Policy Impact

The effective tax rate was 22.2% in Q2 FY26, down from 25.1% in Q2 FY25.

Legal Contingencies

The auditor identified Purchase Price Allocation (PPA) for business combinations (acquisitions) as a Key Audit Matter, involving significant management judgment and estimates.

⚠️ Risk Analysis

Key Uncertainties

Regulatory approval delays for new products (e.g., gSaxenda) and the successful integration of large-scale acquisitions (Biocon, Swiss Parenterals) pose risks to projected EBITDA margins.